TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04543656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-Based Lifestyle Recommendations
Description: The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Lifestyle Recommendations
Description: The control group receives an identical activity tracker and BP monitor in order to objectively assess the effectiveness of the experimental group intervention.
Study: NCT04072796

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
Study: NCT02901106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate
Description: Patient follow-up at 6, 12, 18, 36, and 60 months after the start of Dimethyl fumarate~Systematization of cerebral MRI examination at 18 month and 5 years from the beginning of treatment by Dimethyl fumarate
Study: NCT02060903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abametapir Lotion 0.74% w/w
Description: Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Description: Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.
Study: NCT02859480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5mg
Description: Rosuvastatin 5mg tablet, q.d., for 30 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: Rosuvastatin 5mg tablet, q.d., for 30 months
Study: NCT04400669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Bowel Preparation
Description: oral sodium phosphate (NaP) enema

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low fibre diet
Description: 3 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MBP plus low-fibre diet
Description: 3 days low fibre diet preoperative mechanical bowel preparation
Study: NCT03709940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH
Description: Participants undergo behavioural tests and brain scanning twice, once under placebo and once under an acute dose of MPH, before starting long-term treatment with a long-acting formulation of MPH used routinely at the Adult ADHD Clinic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH
Description: Participants undergo behavioural tests and brain scanning twice, once under placebo and once under an acute dose of MPH, before starting long-term treatment with a long-acting formulation of MPH used routinely at the Adult ADHD Clinic.
Study: NCT02029716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 408 Lotion 0.5%, 1%, 3%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 408 Lotion 0.5%, 1%, 3%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lotion vehicle/placebo
Study: NCT02324140

Intervention type: OTHER
Intervention: Whole blood analysis
Description: In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.

Intervention type: OTHER
Intervention: Whole blood analysis
Description: In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.

Intervention type: OTHER
Intervention: Whole blood analysis
Description: In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.

Intervention type: OTHER
Intervention: Whole blood analysis
Description: In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.
Study: NCT03456791

Intervention type: DIAGNOSTIC_TEST
Intervention: Human epididymis protein 4
Description: Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method

Intervention type: DIAGNOSTIC_TEST
Intervention: Human epididymis protein 4
Description: Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method
Study: NCT04195451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live-Video-Supervised Exercise Intervention
Description: The live-video-supervised exercise intervention includes exercise sessions x3/week for 3 months, and then maintenance regimen for 6 months. Maintenance includes live-video-supervised exercise sessions, only x1/week, and self-exercise x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care then Live-Video Supervised Exercise Intervention
Description: Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the live-video-supervised exercise intervention that includes exercise sessions x3/week for 3 months.
Study: NCT03957707

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: stereotactic surgery plus thrombolysis
Description: stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stereotactic surgery plus thrombolysis
Description: stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
Study: NCT01374620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel dose escalation
Description: Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.~The Paclitaxel dose (mg/infusion) levels are as follows:~* 40~* 60~* 70~* 75~* 80~* 85~* 90

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: D1 to D28: 50 mg x 2/day/cycle~1 cycle = 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: D1 to D28: 50 mg x 2/day/cycle~1 cycle = 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
Study: NCT00642577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 125mg/m2 iv weekly for 4 weeks of each 6 week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: 125mg/m2 iv weekly for 4 weeks of each 6 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 20mg/m2 iv weekly for 4 weeks of each 6 week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: 20mg/m2 iv weekly for 4 weeks of each 6 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 500mg/m2 iv weekly for 4 weeks of each 6 week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 500mg/m2 iv weekly for 4 weeks of each 6 week cycle
Study: NCT02899910

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Education on lifestyle changes for treatment of metabolic syndrome

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Education on lifestyle changes for treatment of metabolic syndrome

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Training in the practice of yoga for treatment of metabolic syndrome
Study: NCT02715414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Family Group + Clinic Implementation Team
Description: Clinic Implementation Teams (CIT) include providers at the clinic that aim to enhance uptake and implementation of MFG through modifications of MFG (e.g., format, length of sessions), but no modification to content will occur.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MFG
Description: MFG is a 12-week group involving 6-8 families of children with problem behaviors. MFG aims to reduce family-level factors that are associated with the onset and perpetuation of problem behaviors. Eight of the 12 sessions are devoted to rules, responsibilities, respectful communication and relationships. Four additional sessions target family stress and social support.
Study: NCT03117712

Intervention type: DIAGNOSTIC_TEST
Intervention: Delirium Scores
Description: * Confusion Assessment method for the ICU (CAM-ICU) and~* The Intensive Care Delirium Screening Checklist (ICDSC)~Delirium Scores will be measured at the following timepoints:~1. Postoperative day (POD) 1~2. POD 2~3. POD 5

Intervention type: DIAGNOSTIC_TEST
Intervention: Delirium Scores
Description: * Confusion Assessment method for the ICU (CAM-ICU) and~* The Intensive Care Delirium Screening Checklist (ICDSC)~Delirium Scores will be measured at the following timepoints:~1. Postoperative day (POD) 1~2. POD 2~3. POD 5

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotis duplex sonography
Description: Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:~1. Before induction of anaesthesia~2. Before going on cardiopulmonary bypass (CBP)~3. During CPB, 5 min after aortic cross clamping~4. After CPB~5. 24 hours after CPB

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotis duplex sonography
Description: Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:~1. Before induction of anaesthesia~2. Before going on cardiopulmonary bypass (CBP)~3. During CPB, 5 min after aortic cross clamping~4. After CPB~5. 24 hours after CPB

Intervention type: DIAGNOSTIC_TEST
Intervention: TCD for detection of HITS
Description: Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:~1. During cannulation of the ascending aorta~2. After aortic cross-clamp~3. After opening of the aortic cross-clamp~4. During decannulation
Study: NCT03239704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Follow-Up
Description: Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Monitoring
Description: Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 30 Day Comprehensive Questionnaire
Description: Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30 Day Comprehensive Questionnaire
Description: Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
Study: NCT04495140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PF-06882961, 50 mg
Description: A single oral dose of \[14C\]PF-06882961, will be administered as a liquid formulation.
Study: NCT03117712

Intervention type: DIAGNOSTIC_TEST
Intervention: TCD for detection of HITS
Description: Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:~1. During cannulation of the ascending aorta~2. After aortic cross-clamp~3. After opening of the aortic cross-clamp~4. During decannulation
Study: NCT04495140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961, 50 mg and [14C]PF-06882961, 100 ug
Description: A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961 will be administered via intravenous infusion.
Study: NCT03306498

Intervention type: DRUG
Intervention: Aminoleban (8% amino acids infusion)
Description: Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
Study: NCT00075140

Intervention type: GENETIC
Intervention: Mutation in the gene
Study: NCT01214356

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
Study: NCT00498602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001 + QS-21
Description: IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: QS-21
Description: IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52

Intervention type: OTHER
Group type: OTHER
Intervention: Diluent: Phosphate Buffered Saline
Description: IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
Study: NCT02248389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonatherm 600i ablation system
Description: HIFU ablation of tumor.
Study: NCT02175498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoeopathic medicines
Description: 4 pills once a week of the indicated Similimum
Study: NCT03109587

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx
Description: 900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
Study: NCT02697968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Study: NCT03233152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab (YervoyTM, 50 mg/10 mL solution)
Description: Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).~Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (OpdivoTM, 40 mg/4mL solution)
Description: First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
Study: NCT02343666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-Benzylguanine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC
Study: NCT01478594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Capsules for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
Study: NCT02575365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 mg Fingolimod
Description: 0.5 mg p.o fingolimod daily
Study: NCT02224469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECoG (electrocorticography) sensing
Description: Implant electrodes and sensing device and use for control of Assistive Technology
Study: NCT02301806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dieting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dieting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: sitagliptin 50 mg tablet by mouth 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: glimepiride 1 mg tablet by mouth 12 weeks
Study: NCT01928875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AoA Monitoring
Description: Monitoring with Entropy and SPI parameters during surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine (Standard) Anesthesia Monitoring
Description: Standard of care monitoring
Study: NCT00830856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole 800mg po qday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole 800mg po qday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose - Stavudine, lamivudine and Nevirapine
Description: Initiation within 72 hours of diagnosis of Cryptococcal meningitis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose - Stavudine, Lamivudine, Nevirapine
Description: Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
Study: NCT04069806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: preoperative oral carbohydrate, preOp
Description: Patients in the experimental arm will receive oral carbohydrate preparation at 2 hours prior to planned caesarian section.